Advertisement


Sumanta K. Pal, MD, and A. Oliver Sartor, MD, on Prostate Cancer: Perspectives on Outcomes for Black and White Patients

2018 ASCO Annual Meeting

Advertisement

Sumanta K. Pal, MD, of City of Hope, and A. Oliver Sartor, MD, of Tulane University School of Medicine, discuss the implications of findings on black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).



Related Videos

Lymphoma
Immunotherapy

Laurie Helen Sehn, MD, MPH, on FL and DLBCL: Results From a Treatment Trial

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses phase II study findings on polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (Abstract 7507).

Hematologic Malignancies
Immunotherapy

Meletios A. Dimopoulos, MD, on Waldenström’s Macroglobulinemia

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, discusses phase III findings on ibrutinib/rituximab vs placebo/rituximab in Waldenström’s macroglobulinemia (Abstract 8003).

Lung Cancer

Naoki Furuya, MD, PhD, on NSCLC: Results From the NEJ026 Study

Naoki Furuya, MD, PhD, of the St. Marianna University School of Medicine, discusses phase III study findings on a comparison of bevacizumab plus erlotinib to erlotinib in patients with untreated non–small cell lung cancer with activating EGFR mutations (Abstract 9006).

Leukemia
Geriatric Oncology

Courtney Denton Dinardo, MD, on AML: Treatment Study Results

Courtney Denton Dinardo, MD, of The University of Texas MD Anderson Cancer Center, discusses findings on the durable response with venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia (Abstract 7010).

Skin Cancer

Emily S. Ruiz, MD, MPH, on Squamous Cell Carcinoma: Expert Perspective

Emily S. Ruiz, MD, MPH, of Brigham and Women’s Cancer Center, discusses new developments in the treatment of squamous cell skin cancer and what she sees on the therapeutic horizon (Abstracts e18703, 9519, and 9577).

Advertisement

Advertisement



Advertisement